Morphocell Technologies

Job Opening at Morphocell Technologies Scientist I - Preclinical Translation As a Scientist I on the Preclinical Translation team, you will play a central role in assessing the safety and efficacy of our groundbreaking treatments. Your expertise will shape development of clinically relevant disease models through execution of preclinical studies. This role offers a unique opportunity to contribute to cutting-edge cell therapies while thriving in a collaborative and innovative environment.   Key Responsibilities:  * Produce iPSC-derived liver tissue for preclinical studies. * Perform basic cell characterization techniques including ddPCR, flow cytometry, ELISA, and potency assays. * Hands-on execution of animal studies, including IP injection, laparotomy, blood and organ collection. * Contribute to the development of in vitro and in vivo preclinical models. * Design, execute, analyze, and report on preclinical studies defining product safety, efficacy, dose, and mechanism of action. * Collaborate closely with Process & Analytical Development, Regulatory, and Clinical teams. * Remain current on emerging technologies, and scientific approaches that enable lean development. * Contribute to a culture of continuous improvement, scientific rigor, respect, and trust. Qualifications:    * Ph.D. in Biological Sciences, Stem Cell Biology, Pharmacy, or a related fields with 1+ years of preclinical development experience. * Demonstrated success designing and executing experiments resulting in key scientific contributions. * Effective use of statistical methods for data analysis, interpretation, and presentation. * Previous exposure to cell therapy development is highly desirable. * Proficient at cultivating, differentiating, and characterizing human iPSCs and derivatives. * Background developing in vitro and in vivo models and/or performing preclinical studies. * Experience with in vivo rodent models, including drug administration and surgical procedures. * Solid analytical and critical thinking skills with the ability to effectively troubleshoot and solve problems, as well as proactively identify risks and propose mitigation solutions. * Excellent written and verbal communication skills with experience presenting data sets to an audience with multidisciplinary backgrounds. * Well organized with efficient time management skills including the ability to prioritize effectively. Please see job posting and apply through link below: https://lnkd.in/etqzwpaN

We’re proud to announce a new international collaboration between CHU Sainte-Justine, UCL/GOSH, and Morphocell Technologies, supported by CQDM and the Stem Cell Network, to advance the development of ReLiver® for children with urea cycle disorders (UCDs) — a group of devastating metabolic diseases. With $727,507 in joint funding, this project will explore ReLiver® as a life-saving, off-the-shelf therapy to help vulnerable newborns survive their first metabolic crises and reach curative treatments such as gene therapy. 🌱🧬 💡 Learn more about the collaboration, the science behind ReLiver®, and what this means for the future of pediatric care: 🔗 https://lnkd.in/g8VU9xqH #RegenerativeMedicine #CellTherapy #UCD #RareDiseases #LiverHealth

Vincent Ling, Ph.D. will be representing Morphocell Technologies at Bio International 2025, June 16 - 19. We will be located at the Quebec Pavilion, Kiosk # 1048, sponsored by Investissement Quebec International.

Advanced Regenerative Manufacturing Institute - Annual Event - May 20 to 22, 2025.

https://lnkd.in/ezSE4utr

Open Position - April 16, 2025 - As a Scientist I in the Process & Analytical Development (PD) team, you will be responsible for providing technical expertise in the creation and optimization of manufacturing processes crucial for the production of cutting-edge cell therapies for liver disease. Collaborating closely with multidisciplinary teams, you will contribute to the design, execution, and improvement of the final drug product (the ReLiver®), ensuring process scalability, reproducibility, and regulatory compliance. This role offers a unique opportunity to make a significant impact on patient care while developing your skills in a dynamic and collaborative environment. Please see PDF for details or visit https://lnkd.in/ex-hZiSj to apply.

Rosa, a grandmother faced acute liver failure after a medication reaction—her family feared the worst. But thanks to groundbreaking advancements in #RegenerativeMedicine, there is new hope for patients like her. 💡 Introducing ReLiver® by Morphocell Technologies — a stem cell-derived engineered liver tissue that temporarily restores liver function, allowing the liver to regenerate, potentially reducing the need for #LiverTransplants. In 2024, Morphocell achieved a major milestone with a $40M investment to bring this life-saving technology to #ClinicalTrials. The future of liver disease treatment is here — and it's more promising than ever. 👉 Read more about this breakthrough in our latest Insights Blog! https://lnkd.in/eE9R3YNT Vincent Ling Massimiliano Paganelli

Christopher Skeete - Morphocell Technologies Le 24 mars 2025, Christopher Skeete, ministre québécois responsable de l’Économie et de l’Innovation, a annoncé le renouvellement du soutien du gouvernement provincial au CQDM et aux autres RSRI. Morphocell a été invitée par le CQDM à présenter son système d’implant ReLiver. Nous avons eu le plaisir de recevoir la visite du ministre Skeete et de lui présenter la science derrière notre approche de médecine régénérative. On March 24, 2025, Christopher Skeete, Quebec Minister Responsible for the Economy & Innovation announced the provincial government renewed support for CQDM and other RSRIs. Morphocell was invited by CQDM to showcase its ReLiver implant system. We were happy to receive a visit from Minister Skeete and illustrate the science behind our regenerative medicine approach.

Morphocell Technologies and BioSurfaces enter into a collaboration exploring regenerative medicine technology.